Nearly 1 in 3 Stop SGLT2 Inhibitors Within a Year in Real-World Diabetes Study, and Most Don’t Restart Treatment - Medscape

Comentar en el chat

1fuente

1país

1idioma

03:04detectada el 08/10 (09:04 UTC)

03:04última novedad, 08/10

1noticia

La publicó primero Medscape (Etiopía) el 08/10 a las 03:04 (09:04 UTC).

03:0408/10, 09:04 UTC

MEMedscape news.google.com ET EN Primera
Nearly 1 in 3 Stop SGLT2 Inhibitors Within a Year in Real-World Diabetes Study, and Most Don’t Restart Treatment - Medscape

Datos de esta historia: JSON